Two Sigma Advisers
FDMT icon

Two Sigma Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

Two Sigma Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-275,300
Closed -$2.06M – 752
2025
Q4 		$2.06M Sell
275,300
-274,400
-50% -$2.78M ﹤0.01% 1177
2025
Q3 		$4.78M Sell
549,700
-193,700
-26% -$1.16M 0.01% 765
2025
Q2 		$2.76M Buy
743,400
+253,000
+52% +$889K 0.01% 986
2025
Q1 		$1.58M Buy
490,400
+364,000
+288% +$1.71M ﹤0.01% 1254
2024
Q4 		$704K Buy
126,400
+103,500
+452% +$812K ﹤0.01% 1628
2024
Q3 		$248K Buy
+22,900
New +$380K ﹤0.01% 1994
2023
Q4 		– Sell
-87,200
Closed -$1.11M – 2548
2023
Q3 		$1.11M Sell
87,200
-25,146
-22% -$421K ﹤0.01% 1474
2023
Q2 		$2.03M Buy
112,346
+12,346
+12% +$227K 0.01% 1194
2023
Q1 		$1.72M Buy
100,000
+77,900
+352% +$1.51M ﹤0.01% 1348
2022
Q4 		$491K Buy
+22,100
New +$341K ﹤0.01% 1883

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Advisers's FDMT Position: Q1 2026 in Review

Two Sigma Advisers sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 275,300 shares — an estimated $2.06M sold.

Two Sigma Advisers first reported a position in FDMT in Q4 2022 and held it in 10 quarters. The position peaked at $4.78M in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Two Sigma Advisers reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 275,300 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.06M.
  • Two Sigma Advisers first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 10 quarters.
  • Two Sigma Advisers's 4D Molecular Therapeutics position peaked at $4.78M in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.